Unknown

Dataset Information

0

Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association.


ABSTRACT: Maintenance of genomic integrity is essential for the survival of all organisms. Homologous recombination (HR) is the major pathway for high-fidelity repair of DNA double-stranded breaks (DSBs). In addition to the classic BRCA-RAD51 pathway, another secondary HR sub-pathway dependent on RAD52 has been suggested to be functioning in mammalian cells. Importantly, RAD52 has been shown to be synthetically lethal to BRCA1/2-deficient cells, rendering RAD52 to be a desirable target in cancer therapy. In the current study, we performed a structure-based virtual screening of 47 737 drug-like compounds to identify RAD52-specific inhibitors. The top ranked virtual screening hits were further characterized using molecular dynamics simulation and biochemical and cell-based assays. We found that one compound, namely, F779-0434 specifically suppressed the growth of BRCA2-deficient cells and disrupted RAD52-ssDNA interaction in vitro. This RAD52-specific inhibitor identified in the current study is a promising compound for targeted cancer therapy, and it can also be used as a probe to study the mechanisms of DNA repair in human cells.

SUBMITTER: Li J 

PROVIDER: S-EPMC9080615 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association.

Li Jian J   Yang Qianye Q   Zhang Yang Y   Huang Kejia K   Sun Rong R   Zhao Qi Q  

RSC advances 20180523 34


Maintenance of genomic integrity is essential for the survival of all organisms. Homologous recombination (HR) is the major pathway for high-fidelity repair of DNA double-stranded breaks (DSBs). In addition to the classic BRCA-RAD51 pathway, another secondary HR sub-pathway dependent on RAD52 has been suggested to be functioning in mammalian cells. Importantly, RAD52 has been shown to be synthetically lethal to BRCA1/2-deficient cells, rendering RAD52 to be a desirable target in cancer therapy.  ...[more]

Similar Datasets

| S-EPMC8118686 | biostudies-literature
| S-EPMC6082171 | biostudies-literature
| S-EPMC4982760 | biostudies-literature
| S-EPMC10185344 | biostudies-literature
| S-EPMC10760972 | biostudies-literature
| S-EPMC4872086 | biostudies-literature
| S-EPMC10654933 | biostudies-literature
| S-EPMC11903656 | biostudies-literature
| S-EPMC8122931 | biostudies-literature
2023-09-21 | GSE207298 | GEO